Intra-tumor combined administration of SLC and anti-CD25 mAb significantly reduced the frequency of Treg and increased the number of CD8+ and CD4+ T cells in tumor sites, and also maximally inhibited the growth and invasion of HCC. This evidence concerns the gene CD4 and hepatocellular carcinoma.